# Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

> **NCT05521984** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Pediatric Brain Tumor
- Pediatric Solid Tumor

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Carmustine
- **DRUG:** Topotecan
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05521984
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2031-03-31
- **Final completion:** 2031-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05521984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05521984, "Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05521984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*